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(57) ABSTRACT 
A method is provided for suppressing atherogenesis in 
Which [a cholesterol 20-hydroperoxide is administered, 
Which is preferably one or both of the novel compounds: 
20(R)-hydroperoxy-25-hydrocholesterol and 29(S) 
hydroperoxy-25-hydrocholesterol] 20(R)-hydroperoxy-25 
hydrocholesterol and 20(S)-hydroperoxy-25 
hydrocholesterol are administered. The compositions 20(R) 
hydroperoxy-ZS-hydrocholesterol and 20(S)-hydroperoxy 
25 -hydrocholesterol are also provided. 
8 Claims, No Drawings 
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20- (B) -20,25-DIHYDROPEROXY-3[3 
HYDROXYCHOLEST-S-ENE AND 20-(S)-20, 
ZS-DIHYDROPEROXY-SB 
HYDROXYCHOLEST-S-ENE 
Matter enclosed in heavy brackets [ ] appears in the 
original patent but forms no part of this reissue speci? 
cation; matter printed in italics indicates the additions 
made by reissue. 
FIELD OF INVENTION 
The ?eld of the invention is medicine agents and methods 
for combatting atherogenesis. 
BACKGROUND OF INVENTION 
The role of cholesterol oxidation products in atherogen 
esis has long been a controversial topic. Peng and Taylor 
(1983), for example, hypothesized that cholesterol oxidation 
products may be responsible for an initial arterial cell injury 
that eventually results in atherosclerosis. On the other hand, 
Higley et al. (1986) disputed that hypothesis, claiming 
instead that oxidized cholesterol is substantially less athero 
genic than puri?ed cholesterol. The analysis of the oxidized 
cholesterol shoWn in Table 1 of Higley et al. indicated the 
presence of diols and epoxides (78%) as the major oxidized 
compounds With a minor amount of hydroperoxide (18%) 
identi?ed as 7ot-hydroperoxide. 
Hypercholesteroloemia is Widely considered to be a major 
risk factor for the development of atherosclerosis. The 
loWering of blood cholesterol levels has therefore been an 
important goal in the search for Ways to prevent or treat 
atherosclerosis. Medicinal agents reported as reducing 
development of athersclerotic lesions typically result in the 
loWering of blood cholesterol levels. Bene?cial agents 
Which do not affect blood cholesterol are rare. But Bell and 
Schaub (1986) have reported that chlorpromazine reduced 
the development of such lesions in rabbits fed an athero 
genic diet Without loWering of blood cholesterol. Chlorpro 
mazine may function as an inhibitor of calmodulin (Gietzen, 
1986) but it is classi?ed pharmacologically as a tranquilizer 
and sedative (Merck Index, 1976), and therefore is not likely 
to be useful as a treatment for atherosclerosis. 
Tipton, et al. (1987), have reported that a mixture of 
cholesterol auto-oxidation products prepared from an aged 
sample of cholesterol inhibits calmodulin irreversibly in a 
Ca2+-dependent reaction. The reactive material Was 
destroyed by chemical reduction. It Was concluded that the 
calmodulin inhibition Was due to one or more cholesterol 
hydroperoxides. The mixture of cholesterol hydroperoxides 
Was further puri?ed by chromatography and used in feeding 
experiments With rabbits. Three diets Were compared, one 
With added cholesterol, one With added cholesterol 
hydroperoxides, and the third With both the cholesterol and 
cholesterol hydroperoxides. The diet containing cholesterol 
alone Was found to have caused extensive atheroma 
formation, While the addition of the cholesterol hydroper 
oxides to the cholesterol diet markedly reduced atheroma 
formation. The cholesterol hydroperoxides Were not found 
to loWer cholesterol concentration in blood plasma, liver or 
heart. In a related experiment, it Was found that the chemi 
cally reduced hydroperoxides Were not effective in reducing 
atheroma formation. 
Cholesterol oxidizes readily in contact With air, and the 
oxidation proceeds at ambient room temperature. The oxi 
dation products as initially formed are largely cholesterol 
hydroperoxides. See Smith, “Cholesterol Autooxidation” 
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(1981, Plenum Press, NeW York). This reference lists the 
initial auto-oxidation products in Table 11, pages 238 to 239. 
These included 3[3-hydroxycholest-5-ene-7ot 
hydroperoxide; 3[3-hydroxycholest-5-ene-7[3 
hydroperoxide; and 3[3-hydroxycholest-5-ene-25 
hydroperoxide, Which is presently preferred for use in this 
invention. Other hydroperoxides included 
3 [3 -hydroxycholest-5-ene- 17-hydroperoxides; 
3 [3 -hydroxycholest-5-ene-20-hydroperoxides; 
3[3-hydroxycholest-5-ene-22-hydroperoxides; and 
3[3-hydroxycholest-5-ene-24-hydroperoxides. 
When it is desired to accelerate the oxidation of choles 
terol to hydroperoxides, a photochemical oxidation proce 
dure can be employed as described by Schenk et al. (1958). 
This reference describes the preparation and isolation of 
3[3-hydroxycholest-5-ene-7ot-hydroperoxide. The 7-6 iso 
mer of this compound can be synthesized and isolated as 
described by Teng et al. (1973). Other cholesterol hydrop 
eroxides can be prepared as an oxidized mixture, and 
separated by fractionation. See van Lier et al. (1970). 
SUMMARY OF INVENTION 
This invention is based in part on the discovery of a novel 
class of cholesterol hydroperoxide compounds in Which the 
hydroperoxide group is in the 20-position and the com 
pounds also contain other added oxygenation. As far as is 
knoWn, no oxidized derivatives of cholesterol have hereto 
fore been reported containing [a ZO-hydroperoxy group 
together With a 25-hydroxyl group. An example of such 
novel compounds is 20-hydroperoxy-25-hydroxycholesterol 
Which has tWo isomeric forms (R and S). Speci?c com 
pounds are 20(R)-hydroperoxy-25-hydroxycholesterol and 
20(S)-hydroperoxy-25-hydrocholesterol. These compounds 
can also be named as: 20-(R)-hydroperoxy-cholest-5-ene 
3[3,25-diol, and 20(S)-hydroperoxy-cholest-5-ene-3[3,25 
diol.] hydroperoxy groups at two positions. An example of 
such novel compounds is 20,25-dihydroperoxy cholesterol 
which has two isomeric forms (20 R and 20 S). Speci?c 
compounds are 20-(R)-20,25-dihydroperoxycholesterol and 
20-(S)-20,25-dihydroperoxycholesterol. These compounds 
can also be named as: 20-(R)-20,25-dihydroperoxy-3B 
hydrocholest-S-ene and 20(S)-20,25-dihyroperoxy-3[3 
hydroxycholest-S-ene. 
The ZO-hydroperoxy cholesterol compounds of this 
invention are highly active as calmodulin inhibitors, and 
also display a high level of activity as inhibitors of acyl 
CoAzcholesterol acyl transferase (ACAT). ACAT is an index 
for anticholesterol therapeutic agents (Suckling et al., 1985). 
The novel compounds of this invention are therefore 
believed to be useful as therapeutic agents for suppressing 
atherogenesis in human patients. 
EXPERIMENTAL BASIS OF INVENTION 
Isolation 
The starting material is cholesterol that has been “aged” 
in air at room temperature for a long time (in this case 20 
years) or cholesterol that has been heated at 55—60 C. in the 
dark in a thin layer for 14 days. 
The starting material is dissolved in boiling methanol, 30 
ml per gram of starting material; the solution is cooled 
sloWly to 4 C. to alloW crystallization of unchanged cho 
lesterol. The cholesterol is removed by vacuum ?ltration and 
the ?ltrate is reduced to one eighth the original volume by 
distillation on a rotary evaporator under reduced pressure. 
After cooling the concentrated ?ltrate to 4 C., a second crop 
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of cholesterol is removed by vacuum ?ltration. The ?ltrate 
from this step is extracted three times With hexane and the 
methanol-rich (loWer) layer is evaporated to dryness under 
vacuum With a rotary evaporator to yield 2.5 g of residue 
from 50 g of starting material. 
This mixture is fractionated by ?ash chromatography on 
silicic acid (60—230 mesh, 200 g) eluted With hexane, 
2-propanol mixtures according to the folloWing protocol: 
hexane-2-propanol ratio, volume, 
v/v ml. 
12:1 260 
11 :1 240 
10 :1 440 
9 :1 500 
6 :1 280 
Elution Was at the rate of 50 mL/min and 50 mL fractions 
Were collected. The desired product elutes in fractions 
16—21, With hexane:2-propanol 10:1 v/v. The combined 
fractions 16—21 are evaporated to dryness to yield about 0.3 
g of material Which is then rechromatographed on silicic 
acid (200—400 mesh, 75 g) With hexane and 2-propanol 
mixtures according to the folloWing protocol: 
hexane-2-propanol ratio, volume, 
v/v ml. 
10 :1 440 
9 :1 250 
8:1 270 
7:1 240 
5:1 240 
The How rate is 20—25 mL/min. After the ?rst 100 mL of 
solvent, one-minute fractions are collected. Elution of the 
hydroperoxides is monitored by thin-layer chromatography 
on silica gel, With benZene and ethyl acetate 3:2 (v.v) as the 
developing solvent. Hydroperoxides are detected by spray 
ing the plates With 1% N,N-dimethyl-p-phenylenediamine in 
methanol and Water 1:1 (v/v) containing 1% acetic acid. The 
desired product elutes in fractions 25—31, With hexane:2 
propanol 8:1 v/v and the yield is 40 mg. 
This mixture is then fractionated by reverse-phase high 
performance liquid chromatography on an Ultrasphere 
(Beckman Instrument Co.) octadecylsilane-treated silica 
column, 4.6 mm><25 cm. Elution is With acetonitrile:Water 
6:4 v/v and the elution is monitored by measuring absor 
bance at 210 nm. Major peaks eluting at about 12.6 and 15.8 
min are collected and designated compounds A and B, 
respectively. The yields from 50 g “aged” cholesterol are 8.9 
mg A and 11.9 mg B. 
The inhibition of calmodulin activity by A and B Were 
measured using the method described by Leung et al. (1984) 
and the results are shoWn in Table 1. 
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TABLE 1 
The inhibitory effect of hydroperoxides A and B on calmodulin. 
The compounds, in the amounts speci?ed, Were preincubated With 
0.3 units of calmodulin followed by calmodulin assay at 30 C. for 30 min. 
nmole P_ 
Treatment produced‘ % inhibition 
Compound A: 
1 ,ug 12.1 92 
0.1 ,ug 16.1 68 
0.01 ,ug 22.9 28 
Compound B 
1 ,ug 13.8 81 
0.1 ,ug 17.3 61 
0.01 ,ug 26.9 4 
Control 27.5 0 
Control + EDTA 10.7 100 
Mass spectra of compounds A and B Were obtained by 
desorption/chemical ioniZation in isobutane. The fragments 
used in elucidating the structure are listed in Table 2. 
TABLE 2 
Mass spectra of Compounds A and B. 
Relative Intensity 
m/Z A B 
433 3.1 0.1 
417 3.9 0.5 
399 9.0 9.0 
401 1.8 1.2 
383 8.7 7.8 
365 8.3 9.2 
317 66.0 42.3 
299 73.9 52.1 
273 73.8 74.5 
255 100.0 100.0 
The tWo compounds have very similar fragmentation 
patterns, suggesting that they are isomers. The fragments 
listed [suggest that the molecular Weight is 434, produced by 
the addition of three atoms of oxygen to cholesterol. Frag 
ments With m/Z 417, 399, 401, 383, and 365 are produced by 
losses of one or tWo molecules of Water, and/or loss of a 
molecule of hydrogen peroxide, from the (M+1) ion, m/Z 
435. The fragment With m/Z 317 is produced by O—O 
cleavage of the —OOH group at C-20 combined With 
cleavage of the C-20, C-22 bond; m/Z 299 is formed by loss 
of Water from this ion. The fragment With m/Z 273 is formed 
by loss of the side-chain (cleavage betWeen C-17 and C-20) 
and m/Z 255 is formed by loss of Water from m/Z 273. These 
fragments shoW that only the side-chain has been modi?ed 
in formation of these compounds from cholesterol, that three 
oxygen atoms have been added, in the form of an alcohol 
and a hydroperoxy group, and that the most likely site of 
attachment of the hydroperoxy group is at C-20.] are best 
interpreted as arising from fragmentation of a molecule of 
molecular weight 450, produced by the addition of four 
atoms of oxygen to cholesterol m/z 433 (M+1—H2O); 417 
(M+1— H202); 399 (M+1—H2O—H2O2); 365 (M+1— 
H2O—2H2O2; 317 (M+1—OH—C22 to C27; 299 (317— 
H20); 273 (M—C2O to C27); 255 (273—H2O). These frag 
ments show that only the side-chain has been modi?ed in 
formation of these compounds from cholesterol, and that 
four atoms of oxygen have been added, in the form of two 
hydroperoxy groups. 
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1H-NMR spectra of the compounds and of cholesterol 
Were obtained and are compared With the spectra of tWo 
diastereomers of 20-hydroperoxycholesterol, reported by 
van Lier and Rousseau (19760, in Table 3. 
TABLE 3 
1H-NMR Spectra of Compounds A and B and reference compounds 
Chemical Shift ppm 20-OOH" 
10 
Cholesterol A B or [5 
C-18 0.674s 0.783s 0.830s 0.79s 0.83s 
C-19 1.003s 1.008s 1.010s 1.02s 1.02s 
C-21 0.810d, J=6.6 1.248s 1.249s 1.25s 1.25s 
C-26, 27 0.858d, J=6.9 1.237s 1.235s 0.88d 0.88d 15 
0.862d, J=6.6 
*20—hydroperoxycholesterol isomers, from van Lier and Rousseau (1976). 
The signal for C-21, Which is a doublet in the spectrum of 
cholesterol, is a singlet in the spectra of compounds A and 
B and the isomers of 20-hydroperoxycholesterol, shoWing 
that the proton on C-20 has been replaced. Similarly, the 
signals for C-26 and C-27, doublets in the spectra of 
cholesterol and 20-hydroperoxycholesterol, coalesce to a 
singlet in the spectra of compounds A and B, shoWing that 
the proton on C-25 has been replaced. 2 
[The hydroperoxy group is shoWn to be at C-20, and the 
hydroxy group at C-25, by the folloWing comparisons 
(Tables 3 and The stereochemistry at C -20 is deduced by 
the following comparisons (Tables 3 and 4). 
20 
30 
TABLE 4 
1H—NMR spectra of the products of reduction of 
compounds A and B by NaBHA and of reference compounds. 
Chemical Shift ppm 20-OH" 35 
Reduced A Reduced B or [5 
C-18 0.87 0.87 0.87 0.87 
C-21 1.29 1.15 1.28 1.13 
40 
*20-Hydroxycholesterol isomers, from Honda nd Komori, 1986 and Nes 
and Varkey, 1976. 
The 1H-NMR spectra of 20-ot- & [3-hydroxycholesterols 
have been compared (Honda and Komori, 1986; Nes and 
Varkey, 1976). Both epimers shoW the same chemical shift 
for protons on C-18, While the protons on C-21 have 
different chemical shifts in the tWo epimers. On the other 
hand, van Lier and Rousseau report that in the tWo epimers 
of 20-hydroperoxycholesterol, the chemical shift for the 
C-21 protons is the same, While the chemical shift for the 
C-18 protons is affected by the stereochemistry at C-20. 
Compounds A and B have the same chemical shift at C-21 
but differ at C-18 While the products of reduction of the 
hydroperoxides to alcohols have the same chemical shift at 
C-18 and differ at C-21. [Therefore the hydroperoxy group 
is at C-20. The stereochemistry at C-20 of Compound A and 
B can also be deduced from the data in Tables 3 and 4.] The 
chemical shift at C-18 of compoundAis further up?eld than 
that of compound B and therefore by analogy With the 
epimers of 20-hydroperoxycholesterol, compound A is the 
[ot isomer (cholest-5-ene-3[3,20S-diol)] 0t isomer (20-(S)-20, 
25 -dihdroperoxy-3[3-hydroxycholest-5 -ene), and compound 
B is the [[3 isomer (cholest-5-ene-3[3,20R-diol)] [3 isomer (20-(R)-20,25-dihydroperoxy-3[3-hydroxycholest-5-ene). 
Comparison of the spectra of the reduction products to those 
of the epimers of 20-hydroxycholesterol con?rms this 
assignment of stereochemistry. 
50 
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COMMERCIAL PRACTICE OF INVENTION 
The novel 20-hydroperoxide cholesterol compounds are 
prepared, puri?ed and isolated as described above for use as 
therapeutic agents in suppressing atherogenesis in human 
patients. [The preferred compounds are 20(S)-hydroperoxy 
cholest-5-ene-3[3,25-diol and 20(R)-hydroperoxy-cholest-5 
ene-3[3-25 diol.] The preferred compounds are 20-(S)-20, 
25-dihydroperoxy-3[3-hydroxycholest-5-ene and 20-(R)-20, 
25-dihydroperoxy-3[3-hydroxycholest-5-ene. These 
compounds may be used separately or in admixture. 
20-hydroperoxy cholesterol compounds of this invention are 
characteriZed by being potent inhibitors of calmodulin, for 
example, by the assay described by Leung et al. (1984). 
They also demonstrate a high level of inhibitory activity in 
the ACAT assay, as described by Mather, et al. (1985). 
The amount of cholesterol 20-hydroperoxide to be admin 
istered can be related to the body Weight and/or the blood 
cholesterol level of the patient. A suf?cient amount of the 
cholesterol hydroperoxide should be administered to be 
effective for reducing aortal deposit of cholesterol. For 
example, from 0.5 to 25 milligrams (mg) of cholesterol 
20-hydroperoxide can be orally administered per kilogram 
(kg) of body Weight per 24 hours. The administration should 
5 be on a regular basis for a period of time as required to 
prevent or treat cholesterol-induced atherogenesis. The cho 
lesterol 20-hydroperoxide may be prepared in the form of 
tablets or capsules. The 20-hydroperoxide compounds can 
be combined With tabletting compositions, viZ. dextrose or 
sucrose, and formed into tablets. Conveniently, the tablets 
may contain an amount of the cholesterol hydroperoxide so 
that 2 to 4 tablets per 24 hours may be taken. For example, 
each tablet may contain 12.5 mg for a tWo tablet dose, or 
6.25 mg of cholesterol hydroperoxide for a four tablet dose 
per 24 hours, or other effective dose amounts. 
The cholesterol-20-hydroperoxides may also be prepared 
in capsule dose form. The capsules can contain only the 
cholesterol 20-hydroperoxide, or it may be admixed With a 
pharmaceutical extender or diluent, such as lactose, 
dextrose, etc. 
For oral administration, either in the form of tablets or 
capsules, the hydroperoxides may be administered in doses 
of from about 0.5 to 25 mg of cholesterol 20-hydroperoxide 
per patient per 24 hours. If the cholesterol 20-hydroperoxide 
composition includes oxidiZed derivatives of cholesterol 
other than the 20-hydroperoxides, dosage should be on the 
basis of the 20-hydroperoxide content only. 
The administration of cholesterol 20-hydroperoxide can 
be monitored if desired. For example, a blood sample can be 
obtained and the serum separated With the lipoproteins 
therein. A portion of the serum can then be subjected to a 
cAMP-phosphodiesterase assay (Sharma & Wang, 1979) to 
measure calmodulin inhibition. 
EXPERIMENTAL EXAMPLES 
The effects of cholesterol hydroperoxides on the esteri? 
cation of cholesterol in mouse peritoneal macrophages Was 
tested as folloWs: 
Monolayers of mouse peritoneal macrophages Were pre 
treated With various concentration of [20-(S)-hydroperoxy 
cholest-5-ene-3[3,25-diol hydroxycholesterol (A) or 20-(R) 
hydroperoxycholest-5-ene-3[3,25 diol 20-(S)-20,25 
dihydroperoxy-3[3-hydroxycholest-5-ene-(A) or 20-(R)-20, 
25-dihydroperoxy-3[3-hydroxycholest-5-ene (B) at 37° C. 
After 15 min preincubation, medium M199 providing 2.5% 
fetal calf serum, acetyl-LDL (25 pig protein/ml) and 
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3H-oleate (0.25 pCi/ml) Was added to the culture dishes. 
After 6 hr of incubation With 5% CO2 at 37° C. the cellular 
lipids Were extracted. This layer chromatography Was used 
to separate cholesteryl ester from other lipid classes before 
the radioactivity Was determined. The activities reported 
have been corrected for losses during chromatography and 
elution of the thin-layer plates. The results are shoWn in 
Table 5. 
TABLE 5 
Concentration Compound A Compound B 
of hydroperoxide, Counts per min 3H 
,uM incorporated into cholesteryl ester 
0 43433 48023 
0 48393 30604 
2.5 55816 41574 
2.5 47673 34918 
5 59136 32751 
10 33700 25140 
10 29618 16252 
25 14510 7752 
25 17621 6232 
50 6059 4073 
50 6059 4073 
75 5074 3177 
75 5047 3385 
100 2830 4427 
100 3970 2401 
Data in Tables 5, 6, and 7 can be supplied in concentration 
units if preferred. It is a simple conversion Which only 
requires the speci?c activities of 3H-oleate and 14C-oleoyl 
coenZyme A, Which are given. 
In a further experiment, the time course of incorporation 
of 3H-oleate into the same cholesterol esters by mouse 
peritoneal macrophages Was studied. Mouse peritoneal mac 
rophages Were gorWn in M199 medium containing 2.5% 
fetal calf serum and acetyl-LDL (25 pg protein/ml) for 18 hr 
at 37° C. The medium Was then replaced by M199 contain 
ing 2.5% fetal calf serum; 3H-oleate With 50 pM compound 
A or 25 pM compound B or no hydroperoxide. At the time 
intervals indicated, the medium Was aspirated and the cel 
lular lipid Was extracted and analyZed by thin-layer chro 
matography. The results are shoWn in Table 6. 
TABLE 6 
Time Counts per minute in cholesterol ester 
min Control Compound A Compound B 
5 3003 2627 2218 
5 3414 1994 1256 
10 4632 2462 2560 
10 4324 3092 2019 
20 8461 6049 4788 
20 15126 5223 3245 
30 8289 4007 3202 
30 10718 2937 2943 
60 40595 4088 5054 
60 16474 5295 7341 
120 38663 7269 7534 
120 40071 10036 9160 
240 57642 19627 18532 
240 66614 17564 15819 
These results of Table 6 shoW that the reaction is linear With 
time up to at least 4 hours. The inhibition due to the 
Compounds A and B is apparent at the shortest time samples 
(5 min.). 
In another experiment, the inhibition of [acrylCoenZyme 
Azcholesterol] acyl-Coenzyme-A:cholesterol acyltransferase 
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(ACAT) by cholesterol hydroperoxides, compounds A and B 
Was used. Mouse liver microsomes (140 pg protein/assay) 
Were treated With various concentrations of compounds A 
and B for 15 min prior to starting the assay by the addition 
of 14C-oleoyl-CoenZyme A (41 pM, 0.068 pCi/assay). The 
reaction Was carried on at 37° C. for exactly 5 min. then 
terminated by the addition of chloroform and methanol. The 
cellular lipids Were extracted and separated by thin-layer 
chromatography. The results are shoWn in Table 7. 
TABLE 7 
Concentration, Counts per minute in cholesterol esters 
,uM Compound A Compound B 
0 5529 4928 
0 5250 5190 
2.5 4702 4557 
2.5 4651 3518 
5 3420 2336 
5 4109 1786 
10 3033 2499 
10 5422 1896 
16.7 1643 920 
16.7 1206 964 
20 1652 523 
20 1708 1067 
25 1121 500 
25 652 720 
33.3 841 429 
33.3 1141 563 
50 632 315 
50 573 294 
100 304 131 
100 297 244 
In a further experiment, the effects of the same cholesterol 
hydroperoxides on the metabolism of acetyl-LDL by mouse 
peritoneal macrophages Was compared. Macrophages Were 
incubated With Compound A (50 pM) or Compound B (25 
pM) and 125I-labelled acetyl-LDL (25 pig in 2 ml) for 6 hr at 
37° C. At the end of the incubation, the medium Was 
removed and proteins Were precipitated from the medium by 
addition of trichloroacetic acid. The cells Were cooled to 4° 
C. and treated With buffer containing 10 mM HEPES and 
heparin to release receptor-bound acetyl-LDL. Finally, the 
cells Were solubiliZed in 0.1N NaOH and the radioactivities 
in each fraction Were measured. The results are shoWn in 
Table 8. 
TABLE 8 
1g Acetvl-LDL/mg protein/6 hr 
heparin 
Treatment soluble Intracellular TCA-soluble 
Control 68 = 2 583 = 28 1899 = 52 
Compound A 125 = 9 630 = 34 1298 = 91 
Compound B 110 = 25 696 = 56 1332 = 225 
Speci?c activity of 1Z5I-acetyl LDL, 315 cpm/ng protein. 
In still another experiment, inhibition of calmodulin by 
the same cholesterol hydroperoxides Was tested. The calm 
odulin inhibition Was assayed as described by Leung et al. 
(J. Biol. Chem., 259:2742—2747, 1984). The results are 
shoWn in Table 9. 
US RE37,999 E 
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TABLE 9 
nmoles phosphate 
Treatment produced % inhibition 
Compound A. 
1 ,ug 12.1 92 
0.1 ,ug 16.1 68 
0.01 ,ug 22.9 28 
Compound B. 
1 ,ug 13.8 81 
0.1 ,ug 17.3 61 
0.001 ,ag 26.9 4 
No addition 27.5 0 
EGTA 10.7 100 
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We claim: 
1. [A method of suppressing atherogenesis in a human 
patient, comprising administering to the patient an amount 
of a cholesterol 20-hydroperoxide selected from the group 
consisting of 20(R)-hydroperoxy-25-hydroxycholesterol, 
20(S)-hydroperoxy-25-hydroxycholesterol and mixtures 
thereof] A method of suppressing atherogenesis in a human 
patient, comprising administering to the patient an amount 
of a cholesterol hydroperoxide selected from the group 
consisting of 20-(R)-20,25-dihydroperoxy-3[3 
hydroxycholest-S-ene, 20-(S) -20, 25-dihydroperoxy-3B 
hydroxycholest-S-ene and mixtures thereof effective for 
reducing aortal deposit of cholesterol, said amount admin 
istered being in a dosage range from 0.5 to 25 milligrams of 
said cholesterol [20-] hydroperoxide per kilogram of body 
Weight per 24 hours. 
2. The method of claim 1 in Which [the] said cholesterol 
[20-] hydroperoxide is administered orally. 
3. Amedication for prevention and/or treatment of athero 
genesis in human patients, comprising an oral dose form of 
cholesterol [20-] hydroperoxide[,] selected from the group 
consisting of 20-(R)-20,25-dihydroperoxy-3[3 
hydroxycholest-S-ene, 20-(S) -20, 25-dihydroperoxy-3B 
hydroxycholest-S-ene and mixtures thereof said dose form 
being selected from tablets and capsules. 
4. The medication of claim 3 in Which said cholesterol 
[20-] hydroperoxide is in admixture With a solid carrier. 
5. The medication of claim 3 in Which said dose form is 
a tablet, and said cholesterol [20-] hydroperoxide is admixed 
With a pharmaceutical tabletting composition. 
6. The medication of claim 3 in Which said dose form is 
a capsule, and said cholesterol [20-] hydroperoxide is 
admixed With a pharmaceutical diluent composition. 
[7. The medication of claims 3, 4, 5, or 6 in Which said 
cholesterol 20-hydroperoxide is selected from the group 
consisting of 20(R)-hydroperoxy-25-hydroxycholesterol, 
20(S)-hydroperoxy-25-hydroxycholesterol, and mixtures 
thereof] 
8. [20(R)-hydroperoxy-25-hydroxycholesterol] 20-(R) 
20, 25 -dihydroperoxy-3 [3 -hydroxycholest-5 -ene. 
9. [20(S)-hydroperoxy-25-hydroxycholesterol] 20-(S)-20, 
25 -dihydroxyperoxy-3 [3-hydroxycholest-5 -ene. 
* * * * * 
